|
US7728013B2
(en)
|
2005-05-10 |
2010-06-01 |
Intermune, Inc. |
Method of modulating stress-activated protein kinase system
|
|
KR101412675B1
(ko)
|
2005-12-21 |
2014-07-03 |
얀센 파마슈티카 엔.브이. |
티로신 키나제 모듈레이터로서의 트리아졸로피리다진
|
|
CA2651979A1
(en)
*
|
2006-05-30 |
2007-12-06 |
Pfizer Products Inc. |
Triazolopyridazine derivatives
|
|
EP2044026B1
(en)
|
2006-06-22 |
2014-03-26 |
Prana Biotechnology Limited |
Method of treatment of glioma brain tumour
|
|
PE20080403A1
(es)
*
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
WO2008011045A2
(en)
*
|
2006-07-18 |
2008-01-24 |
Cytovia, Inc. |
3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
|
|
WO2008021781A1
(en)
|
2006-08-07 |
2008-02-21 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
US8481538B2
(en)
|
2006-09-18 |
2013-07-09 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic inhibitors of c-Met and uses thereof
|
|
SI2497470T1
(sl)
|
2006-11-22 |
2016-02-29 |
Incyte Holdings Corporation |
Imidazotriazini in imidazopirimidini kot inhibitorji kinaz
|
|
JP5550352B2
(ja)
|
2007-03-15 |
2014-07-16 |
ノバルティス アーゲー |
有機化合物およびその使用
|
|
CN101678014B
(zh)
*
|
2007-05-21 |
2012-12-12 |
Sgx药品公司 |
杂环激酶调节剂
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
US8188083B2
(en)
*
|
2007-06-28 |
2012-05-29 |
Abbott Laboratories |
Triazolopyridazines
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
FR2919870B1
(fr)
*
|
2007-08-09 |
2014-05-16 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
|
|
FR2929613B1
(fr)
*
|
2008-04-02 |
2010-12-31 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
|
|
PA8792501A1
(es)
*
|
2007-08-09 |
2009-04-23 |
Sanofi Aventis |
Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
|
|
SI2193133T1
(sl)
|
2007-09-27 |
2015-12-31 |
Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii |
Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
KR20100128305A
(ko)
|
2008-02-28 |
2010-12-07 |
노파르티스 아게 |
Ｃ-ｍｅｔ 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-ｂ]피리다진 유도체
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
WO2009143211A2
(en)
|
2008-05-21 |
2009-11-26 |
Incyte Corporation |
Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
|
|
US8304413B2
(en)
|
2008-06-03 |
2012-11-06 |
Intermune, Inc. |
Compounds and methods for treating inflammatory and fibrotic disorders
|
|
DE102008028905A1
(de)
*
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
|
UY32049A
(es)
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
DE102008038220A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Oxadiazolderivate
|
|
DE102008038222A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Indazol-5-carbonsäurehydrazid-derivate
|
|
RU2011124894A
(ru)
|
2008-11-19 |
2012-12-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Триазолотиадиазоловый ингибитор протеинкиназы с-мет
|
|
WO2010059771A1
(en)
|
2008-11-20 |
2010-05-27 |
Osi Pharmaceuticals, Inc. |
Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
|
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
EA019320B1
(ru)
|
2008-12-22 |
2014-02-28 |
Мерк Патент Гмбх |
Новые полиморфные формы дигидрофосфата 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илэтокси)пиримидин-2-ил]бензил}-2h-пиридазин-3-она и способы их получения
|
|
DE102008062825A1
(de)
*
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
FR2941949B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941951B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941950B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941952B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
CA2749926A1
(en)
|
2009-02-10 |
2010-08-19 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
|
JP2012519731A
(ja)
*
|
2009-03-09 |
2012-08-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ニコチン受容体およびｇａｂａａ受容体のアロステリックモジュレーターとしての置換複素環およびそれらの使用
|
|
CN102388055B
(zh)
|
2009-04-02 |
2015-07-29 |
卡洛斯三世国家癌症研究中心基金会 |
咪唑并[2,1-b][1,3,4]噻二唑衍生物
|
|
AU2010254053A1
(en)
*
|
2009-05-28 |
2011-12-01 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrazole inhibitors of c-Met protein kinase
|
|
CN102448969A
(zh)
|
2009-05-28 |
2012-05-09 |
沃泰克斯药物股份有限公司 |
C-met蛋白激酶抑制剂
|
|
SI2435443T1
(sl)
*
|
2009-05-28 |
2013-12-31 |
Vertex Pharmaceuticals Incorporated |
Aminopirazol triazolotiadiazolni inhibitorji c-met protein kinaze
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
EP2464649A1
(en)
|
2009-08-12 |
2012-06-20 |
Novartis AG |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
|
BR112012008061A2
(pt)
|
2009-08-20 |
2016-03-01 |
Novartis Ag |
compostos de oxima heterocíclica
|
|
EP2519524A4
(en)
|
2009-12-31 |
2013-07-03 |
Hutchison Medipharma Ltd |
CERTAIN TRIAZOLOPYRIDINE AND TRIAZOLOPYRZINE, COMPOSITIONS AND METHOD OF USE
|
|
US8487096B2
(en)
|
2010-02-03 |
2013-07-16 |
Incyte Corporation |
Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors
|
|
EP2569315A1
(en)
|
2010-05-14 |
2013-03-20 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
CA2798080C
(en)
|
2010-05-17 |
2020-08-25 |
Incozen Therapeutics Pvt. Ltd. |
3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
|
|
JP2013527195A
(ja)
*
|
2010-05-27 |
2013-06-27 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｃ−Ｍｅｔプロテインキナーゼのアミノピラゾールトリアゾロチアジアゾールインヒビター
|
|
EP2588107A1
(en)
|
2010-07-01 |
2013-05-08 |
Takeda Pharmaceutical Company Limited |
COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
|
|
AR085183A1
(es)
*
|
2010-07-30 |
2013-09-18 |
Lilly Co Eli |
Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
|
|
WO2012158658A1
(en)
|
2011-05-16 |
2012-11-22 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
SG11201401531RA
(en)
|
2011-11-11 |
2014-07-30 |
Pfizer |
2-thiopyrimidinones
|
|
WO2013134562A1
(en)
|
2012-03-09 |
2013-09-12 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
JP6134376B2
(ja)
|
2012-03-16 |
2017-05-24 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
３，５−ジアミノピラゾールキナーゼ阻害剤
|
|
JP6192708B2
(ja)
|
2012-03-30 |
2017-09-06 |
ライゼン・ファーマシューティカルズ・エスアー |
Ｃ−ｍｅｔプロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
|
|
AR092742A1
(es)
|
2012-10-02 |
2015-04-29 |
Intermune Inc |
Piridinonas antifibroticas
|
|
KR102300675B1
(ko)
|
2012-12-20 |
2021-09-13 |
템페스트 테라퓨틱스, 인코포레이티드 |
트리아졸론 화합물 및 이의 용도
|
|
CA2921420A1
(en)
|
2013-09-06 |
2015-03-12 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
WO2015046653A1
(ko)
|
2013-09-30 |
2015-04-02 |
한국화학연구원 |
신규한 트리아졸로 피라진 유도체 및 그의 용도
|
|
GB201321745D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
WO2015153683A1
(en)
|
2014-04-02 |
2015-10-08 |
Intermune, Inc. |
Anti-fibrotic pyridinones
|
|
WO2016091891A1
(en)
|
2014-12-09 |
2016-06-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against axl
|
|
MY191736A
(en)
|
2014-12-23 |
2022-07-13 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
WO2016161125A1
(en)
|
2015-03-31 |
2016-10-06 |
University Of Vermont And State Agricultural College |
Methods for treating cryptosporidiosis using triazolopyridazines
|
|
JP2018515480A
(ja)
|
2015-05-05 |
2018-06-14 |
ファイザー・インク |
２−チオピリミジノン
|
|
PH12017502322B1
(en)
|
2015-06-25 |
2023-08-30 |
Taiho Pharmaceutical Co Ltd |
Therapeutic agent for fibrosis
|
|
US20180194769A1
(en)
|
2015-07-06 |
2018-07-12 |
Rodin Therapeutics, Inc. |
Hetero-halo inhibitors of histone deacetylase
|
|
US10421756B2
(en)
|
2015-07-06 |
2019-09-24 |
Rodin Therapeutics, Inc. |
Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
|
|
EP3362442B1
(en)
|
2015-10-14 |
2020-01-29 |
Bristol-Myers Squibb Company |
2,4-dihydroxy-nicotinamides as apj agonists
|
|
EP3383860B1
(en)
|
2015-12-04 |
2021-01-20 |
Bristol-Myers Squibb Company |
Apelin receptor agonists and methods of use
|
|
MX380669B
(es)
|
2015-12-16 |
2025-03-12 |
Bristol Myers Squibb Co |
Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
|
|
ES2895124T3
(es)
|
2016-03-24 |
2022-02-17 |
Bristol Myers Squibb Co |
6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas de APJ
|
|
GR1009565B
(el)
*
|
2016-07-14 |
2019-08-06 |
Galenica Α.Ε. |
Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
|
|
HUE057849T2
(hu)
|
2017-01-11 |
2022-06-28 |
Alkermes Inc |
Hiszton deacetiláz biciklusos gátlói
|
|
JP6771594B2
(ja)
|
2017-02-15 |
2020-10-21 |
大鵬薬品工業株式会社 |
医薬組成物
|
|
MX394399B
(es)
*
|
2017-05-26 |
2025-03-24 |
Jiangsu Atom Bioscience And Pharmaceutical Co Ltd |
Inhibidor de urat1 para promover la excresion de acido urico.
|
|
EP3652165B1
(en)
*
|
2017-07-12 |
2021-08-25 |
Bristol-Myers Squibb Company |
Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
|
|
HUE058799T2
(hu)
|
2017-08-07 |
2022-09-28 |
Alkermes Inc |
Hiszton-deacetiláz biciklusos inhibitorai
|
|
EP3682882A4
(en)
|
2017-09-08 |
2021-06-02 |
Taiho Pharmaceutical Co., Ltd. |
ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
|
|
JP7590183B2
(ja)
|
2018-03-13 |
2024-11-26 |
武田薬品工業株式会社 |
血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用
|
|
WO2021055621A1
(en)
|
2019-09-18 |
2021-03-25 |
Shire Human Genetic Therapies, Inc. |
Plasma kallikrein inhibitors and uses thereof
|
|
WO2021055589A1
(en)
|
2019-09-18 |
2021-03-25 |
Shire Human Genetic Therapies, Inc. |
Heteroaryl plasma kallikrein inhibitors
|
|
TR202009388A1
(tr)
|
2020-06-17 |
2021-12-21 |
Anadolu Ueniversitesi |
Akci̇ğer kanseri̇ tedavi̇si̇nde hedefe yöneli̇k yeni̇ tri̇azoloti̇yadi̇azi̇n türevleri̇
|
|
TR202010296A1
(tr)
|
2020-06-30 |
2022-01-21 |
Anadolu Ueniversitesi |
Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri
|
|
EP4288430A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
WO2022197789A1
(en)
*
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Polycyclic inhibitors of plasma kallikrein
|